Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

buprenorphine naloxone

Adjunctive therapy

Brand: Suboxone

Published 2026-02-05 · Last reviewed 2026-02-12 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Treatment is often structured in phases (induction, stabilization, maintenance) with dose changes guided by withdrawal symptoms, cravings, and safety (guideline/clinical).·Half-life: Single-dose range 24–42 h·LAI available: No

Class: Adjunctive therapy
Typical dose: Treatment is often structured in phases (induction, stabilization, maintenance) with dose changes guided by withdrawal symptoms, cravings, and safety (guideline/clinical).
Half-life: Single-dose range 24–42 h
LAI available: No

Quick answers

What is buprenorphine naloxone?: Buprenorphine-naloxone (brand Suboxone; generics) is a combination medication used to treat opioid use disorder (OUD). Buprenorphine is a partial opioid agonist that reduces withdrawal and cravings, while the naloxone component is included to discourage injection misuse (label/guideline).
What is Suboxone?: Suboxone is a brand name for buprenorphine naloxone.
What is Suboxone (buprenorphine naloxone) used for?: Label indications include: Opioid use disorder treatment (induction and maintenance) (label).
What drug class is Suboxone (buprenorphine naloxone)?: Opioid Partial Agonist.
What is the mechanism of action of Suboxone (buprenorphine naloxone)?: Combination of buprenorphine (partial μ-opioid receptor agonist) and naloxone (opioid antagonist) used for treatment of opioid use disorder. Naloxone has low bioavailability sublingually but deters injection misuse (label/guideline).
What strengths does Suboxone (buprenorphine naloxone) come in?: Sublingual film and sublingual tablets (multiple strengths) (label).

General information

Buprenorphine-naloxone (brand Suboxone; generics) is a combination medication used to treat opioid use disorder (OUD) (label).

Buprenorphine is a partial μ-opioid receptor agonist that reduces withdrawal and cravings; naloxone is included primarily to discourage injection misuse (low bioavailability with sublingual use) (label).

Buprenorphine induction timing is clinically important because starting too soon after recent opioid use can trigger precipitated withdrawal; programs typically use structured induction approaches aligned with objective withdrawal (label/guideline).

Safety planning often focuses on sedation/respiratory depression with other CNS depressants, diversion risk, and co-occurring mental health symptoms (label/guideline).

The compare view, buprenorphine-naloxone evidence feed, and buprenorphine-naloxone print page support documentation and counseling when opioid treatment decisions overlap with anxiety, insomnia, and depression symptoms.

U.S. approvals

Opioid use disorder treatment (label)

Formulations & strengths

Sublingual film and sublingual tablets (multiple strengths) (label).

Generic availability

Generic equivalents available in the U.S.

Often used in office-based or program-based opioid use disorder (OUD) treatment. Access, induction logistics (especially with fentanyl exposure), and co-prescribed sedatives are common determinants of safety and outcomes.

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Buprenorphine is a partial μ-opioid receptor agonist with high receptor affinity; it reduces withdrawal and cravings and has a ceiling effect on respiratory depression compared with full agonists (label/guideline).

Naloxone is an opioid antagonist added to discourage parenteral misuse. With sublingual use, naloxone bioavailability is low; if injected, it can trigger precipitated withdrawal (label).

Buprenorphine partial μ-opioid agonism (high affinity); naloxone opioid antagonism.

Metabolism & pharmacokinetics

Buprenorphine is metabolized primarily by CYP3A4 and by glucuronidation pathways (UGT), with elimination via feces and urine (label).
Naloxone undergoes extensive first-pass metabolism and has low bioavailability via the sublingual route (label).
Hepatic impairment can increase exposure; labeling includes cautions and clinicians often monitor liver-related risk when baseline disease is present (label/clinical).

Dosing & administration

Treatment is often structured in phases (induction, stabilization, maintenance) with dose changes guided by withdrawal symptoms, cravings, and safety (guideline/clinical).
Induction timing is individualized by opioid type and timing of last use; objective withdrawal assessment is commonly used to reduce precipitated withdrawal risk (label/guideline).
Follow-up frequency is often higher early in treatment and then adjusted as stability improves (guideline/clinical).

Monitoring & labs

Early follow-up to assess withdrawal control, cravings, sedation, and adherence (guideline/clinical).
Review concurrent CNS depressants at each visit and reassess risk when new sedating medications are started (label/clinical).
Monitor for diversion/misuse as clinically indicated (structured follow-up, PDMP review, urine drug testing depending on setting) (guideline/clinical).
Consider hepatic monitoring when baseline liver disease is present or when symptoms emerge (label/clinical).

Induction and early stabilization are the highest-risk periods; programs often document induction timing decisions to reduce precipitated withdrawal risk (label/guideline).

Adverse effects

FDA boxed warnings

Common side effects (≥10%)

Sedation / dizziness: Can impair driving and work safety, especially early in treatment or with other sedatives (label/clinical).
Constipation / nausea: Opioid-related GI effects can occur; management is commonly discussed as part of retention planning (label/clinical).
Headache / sleep disturbance: Sleep disruption can reflect withdrawal recovery, co-occurring insomnia/anxiety, or medication effects; monitoring often focuses on functional impact (clinical).

Other notable effects

Respiratory depression risk increases with alcohol, benzodiazepines, sedating sleep agents, gabapentinoids, or other opioids (label/clinical).
Precipitated withdrawal can occur if started too soon after full agonist opioid use; induction planning is intended to reduce this risk (label/guideline).
Diversion and misuse risks are part of routine care planning (guideline/clinical).

Interactions

CNS depressants (alcohol, benzodiazepines, sedative-hypnotics, gabapentinoids) can increase sedation and respiratory depression risk (label/clinical).
CYP3A4 inhibitors or inducers can alter buprenorphine exposure; regimen changes often prompt monitoring for withdrawal or over-sedation (label/clinical).

Other useful information

Systematic reviews show buprenorphine maintenance improves retention and reduces illicit opioid use compared with placebo/no medication (review/guideline).
Guidelines emphasize that medication for opioid use disorder is a core treatment and can be effective with or without formal counseling, though many people benefit from additional supports when available (guideline/clinical).
Choice among buprenorphine, methadone, and naltrexone is typically individualized by opioid tolerance, withdrawal severity, access/logistics, and medical risk (guideline/clinical).

References

Related hubs:SMI toolkit·Support resources